RETATRUTIDE

Retatrutide is a next-generation GLP-3 receptor agonist peptide designed to support advanced metabolic optimization, weight management, and appetite regulation. Unlike traditional GLP-1 therapies, Retatrutide activates three key hormone pathways, GLP-1, GIP, and glucagon receptors, working together to help reduce hunger, enhance fat metabolism, improve insulin response, and increase energy expenditure.

This triple-action mechanism supports meaningful body composition changes, sustained weight loss, and improved metabolic health when combined with proper nutrition and lifestyle habits.

Mechanism: Retatrutide simultaneously activates incretin and glucagon signaling pathways that enhance mitochondrial fat oxidation and regulate appetite control centers.

Benefits may include

• Reduced appetite and improved satiety
• Enhanced fat metabolism
• Improved insulin sensitivity
• Increased energy expenditure
• Meaningful body composition changes

Estimated Timeline

Weeks 1–2: Reduced appetite, earlier fullness
Weeks 3–6: Noticeable fat loss and energy stability
Weeks 6–12+: Significant body composition improvements

Typical Use Duration

12–24 weeks depending on goals.

(Use under medical or wellness professional guidance.)